Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy.
A 40-year-old woman had a 10-year history of dermatophyte-related toenail onychomycosis (tinea unguium) and dry-type tinea pedis, which had failed to respond to previous therapy with topical antifungal agents or oral griseofulvin. The patient was successfully treated with four cycles of intermittent itraconazole therapy (that is, 400 mg/d for 1 week per month for 4 months). At the end of this time, the tinea pedis had resolved and the onychomycosis improved significantly after four cycles were completed. Twelve months after the onset of therapy, both conditions had resolved completely according to both clinical and mycologic criteria. Itraconazole was well tolerated, with no side effects reported. These observations suggest that itraconazole intermittent dosing is a highly effective therapy for the treatment of onychomycosis caused by dermatophyte organisms, because it provides a high cure rate after only a short course of therapy.
Del Rosso
J Q
JQ
D000284:Administration, Oral; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005533:Foot Dermatoses / Q000150:complications / Q000188:drug therapy; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage* / Q000627:therapeutic use; D014009:Onychomycosis / Q000150:complications / Q000188:drug therapy*; D014008:Tinea Pedis / Q000150:complications / Q000188:drug therapy*
D000935:Antifungal Agents; D017964:Itraconazole